Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus - Wikidata - wikimedia - TriplyDB

Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus

Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus

http://www.wikidata.org/entity/Q33895494

about

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies Viruses for tumor therapy Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.Oncolytic Poxviruses.Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.Targeting cancer stem cells with oncolytic virus Oncolytic myxoma virus: the path to clinic Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.The current status and future directions of myxoma virus, a master in immune evasion.Oncolytic viral therapy: targeting cancer stem cells Gene and virotherapy for hematological malignancies Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro VSV based virotherapy in ovarian cancer: the past, the present and …future?Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.Panorama from the oncolytic virotherapy summit.Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.

P2860

Q26751959-B5659F40-41A9-44B8-B58E-5DE4843CC903 Q26823826-A99C5BC0-0F3E-47CA-9547-4379797A6814 Q34351517-18C6A046-60DF-484E-9A9E-920D7ED8EE42 Q34384975-E454DE88-7970-40DC-A008-AEE005CCFF4D Q35216344-B04F4F7B-1A8A-474F-AE60-CCFFD7CC6F1D Q35234349-CECABCB4-CEBB-47B2-86AF-F5387B574394 Q36565516-46D188A5-9D2C-453D-BC52-031E369FF17F Q37044088-D77C818B-2D9B-4A70-9AAA-0B3629057943 Q37126088-A21C349A-3C31-4590-BB97-68355E6C8134 Q37481390-9809ACDA-7EEE-4976-BE29-A6BA961A7805 Q37718563-160D2157-E47B-4ED3-8FF5-F95D6633851A Q37787452-29D697E7-B02C-485E-B332-AA4828462A2D Q37887080-59EF3DB3-D3E2-43FC-84AA-A5CA4B395936 Q38212255-A7FA7E59-986D-4C85-9045-B3C5BB1742C3 Q38854625-C485FA31-CEFC-4AE5-BC9C-F87D8E75F64E Q39395568-7800BDBC-8DB4-4597-91F1-D90D0C06CFFE Q41441101-AD25481E-0D5A-44E5-8F2E-C018A5E0D615 Q42144185-54A5B146-F749-410F-9844-1C230ACF6A65 Q42934744-EFD17D82-193A-420C-A17B-B9EFF24D344D Q44837303-7315D972-1B18-473E-80E2-FF32FEFDE02F

P2860

Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus

http://www.wikidata.org/entity/Q33895494

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@ast

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@en

type

label

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@ast

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@en

prefLabel

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@ast

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@en

P1433

Q33895494-89139F69-26AB-4D41-9368-35F6D523A127

P1476

Q33895494-29BF6CD9-B69A-4AE2-A440-BDE1176743C2

P2093

Q33895494-0D9FEBE2-D026-4D1A-92A0-ABA648A0AD66

Q33895494-82842A79-D8AE-431A-AF7C-8C4BA23F5906

Q33895494-C6212F8B-7027-4AAF-86B3-3990DAB958A5

P2860

Q33895494-091581D9-8609-480D-9373-7B4B07B93261

Q33895494-0CFE2276-D9CB-4711-BD52-CAFC4F2AA029

Q33895494-120B590D-9BB4-43D0-9AD4-22D034D3C6F7

Q33895494-125152CE-C7F2-41BD-8F12-547989A8C459

Q33895494-1490D250-05F8-4D5C-A1CE-0D49F33DC328

Q33895494-1591830F-C855-4093-A93C-116A7025FC29

Q33895494-1986E46E-70BA-4957-A355-552E2E52F489

Q33895494-217FDA9A-CD19-429E-AA5D-77F428109E31

Q33895494-22298065-D20E-4296-AA12-6D829D66FC4A

Q33895494-28E27087-8A88-4335-9EFB-59C78B620215

P304

Q33895494-846AC1D0-8AD5-4606-8B99-8DF7F6B0D09A

P31

Q33895494-9B014875-1CC0-48B9-9FD4-09BC0C8C48C5

P356

Q33895494-5F5FBEC1-8166-403E-8B4C-9B0F9D1C8DE2

P433

Q33895494-4676A356-8316-43E8-B660-2E76D228C481

P478

Q33895494-176518D5-2C68-4B8C-A998-3CD8E9406C31

P50

Q33895494-26CACA31-F320-41F8-8877-67C3D2167A53

P577

Q33895494-BD39330A-28AD-4218-8EBD-B5FBAA23F926

P5875

Q33895494-37579C1E-2C39-4499-9C9F-83493F3B9609

P698

Q33895494-9962B4A0-535F-47AA-8416-94E804E138FB

P921

Q33895494-24CD5BDD-AE19-4035-A6D4-1BA24D598BF7

Q33895494-5C76DE54-D35C-4D55-BCC9-87EAADD2A9EB

P932

Q33895494-0FA9C4BD-0D6A-4EFD-A71A-45F4C09F93EA

P356

J.CYTOGFR.2010.02.010

P1433

Cytokine and Growth Factor Reviews

P1476

Oncolytic viral purging of leu ...... enitor cells with Myxoma virus

@en

P2093

Christopher R Cogle

http://www.w3.org/2001/XMLSchema#string

Gerard J Madlambayan

http://www.w3.org/2001/XMLSchema#string

Masmudur M Rahman

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of the PI3K/Akt Pathway Early during Vaccinia and Cowpox Virus Infections Is Required for both Host Survival and Viral Replication

Poxvirus tropism

Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer

RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages

Adventures with poxviruses of vertebrates.

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses

P304

169-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CYTOGFR.2010.02.010

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41824955

http://www.w3.org/2001/XMLSchema#string

P698

20211576

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2881168

http://www.w3.org/2001/XMLSchema#string